Literature DB >> 7594709

Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study.

M Dorrucci1, P Pezzotti, A N Phillips, A C Lepri, G Rezza.   

Abstract

To assess the influence of hepatitis C virus (HCV) on the natural history of human immunodeficiency virus (HIV) infection, a longitudinal study was conducted among 416 HIV-positive, AIDS-free persons infected through injecting drug use or homosexual or heterosexual activity and with known seroconversion dates. End points were diagnosis of AIDS and a CD4 cell count of < 100 x 10(6) cells/L. HCV antibodies were detected in 214 persons (51.4%). The crude relative hazard (RH) of progression to AIDS was 0.96 (95% confidence interval [CI], 0.53-1.76) for HCV-coinfected participants compared with those not coinfected. After adjustment for CD4 cell count, the RH was 0.97 (95% CI, 0.52-1.79). Similar RHs were found using a CD4 cell count of < 100 x 10(6) cells/L as the end point. The median CD4 cell loss was 4.83 x 10(6) cells/L per month among coinfected persons and 5.70 x 10(6) cells/L per month among the others. These results suggest that coinfection with HCV does not influence clinical and immunologic progression of HIV disease.

Entities:  

Mesh:

Year:  1995        PMID: 7594709     DOI: 10.1093/infdis/172.6.1503

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

Review 1.  Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infections.

Authors:  K E Nelson; D L Thomas
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

2.  Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters.

Authors:  Helen M Chun; Mollie P Roediger; Katherine Huppler Hullsiek; Chloe L Thio; Brian K Agan; William P Bradley; Sheila A Peel; Linda L Jagodzinski; Amy C Weintrob; Anuradha Ganesan; Glenn Wortmann; Nancy F Crum-Cianflone; Jason D Maguire; Michael L Landrum
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

Review 3.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

4.  Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count.

Authors:  S Mauss; H Klinker; A Ulmer; R Willers; B Weissbrich; H Albrecht; D Häussinger; H Jablonowski
Journal:  Infection       Date:  1998 Jan-Feb       Impact factor: 3.553

5.  Management of Hepatitis C in HIV-infected Patients.

Authors:  Benigno Rodriguez; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

Review 6.  Hepatitis C virus infection in HIV-infected patients.

Authors:  Mark S Sulkowski
Journal:  Curr HIV/AIDS Rep       Date:  2004-09       Impact factor: 5.071

7.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.

Authors:  Lena Al-Harthi; John Voris; Wenbo Du; David Wright; Marek Nowicki; Toni Frederick; Alan Landay; Andrea Kovacs
Journal:  J Infect Dis       Date:  2006-03-17       Impact factor: 5.226

9.  Anti-HCV antibody among newly diagnosed HIV patients in Ughelli, a suburban area of Delta State Nigeria.

Authors:  Ogbodo Ekene Newton; Otue Akpevwe Oghene; Iheanyi Omezuruike Okonko
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

10.  Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern China.

Authors:  Rebecca-J Garten; Sheng-Han Lai; Jin-Bing Zhang; Wei Liu; Jie Chen; Xiao-Fang Yu
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.